Skip to main content

Advertisement

SpringerLink
Log in

Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Resectable esophageal adenocarcinoma (EAC) patients often receive chemoradiation followed by surgery. However, most patients experience recurrences. Overexpression of MTDH, an oncoprotein with multiple functions, has been found to be associated with poor prognosis in breast cancer, glioblastoma, melanoma and various gastrointestinal malignancies, but not in EAC. We sought to establish its role in resistant EAC (post-treatment residual EAC). MTDH was assessed by immunohistochemistry in resected EAC, and results were correlated with clinical outcomes. MTDH expression was detectable in 72.5% (50/69) of patients, while expression levels were high (positive) in 50.7% (35/69). Of 69 patients analyzed, 25 had no relapse and 44 patients had a relapse (8 with local–regional and 36 with distant). The median follow-up duration was 3 years (0.4–11.6). The median overall survival was not associated with MTDH status (2.79 years for MTDH-negative and 3.60 years for MTDH-positive patients, p = 0.121). In addition, MTDH was not associated with either the type of relapse (local or distant), baseline clinical stage, tumor grade, presence of signet ring cells, surgical (yp) stage, percentage of residual EAC or presence of lymphovascular invasion. Our data reveal that MTDH is not a prognostic biomarker in resistant EAC after trimodality therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    Article  PubMed  Google Scholar 

  2. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: Are we reaching the peak? Cancer Epidemiol Biomark Prev. 2010;19:1468–70.

    Article  Google Scholar 

  3. Ajani JA, D’Amico TA, Almhanna K, et al. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Cancer Netw. 2015;13:194–227.

    Article  CAS  Google Scholar 

  4. Su ZZ, Kang DC, Chen Y, et al. Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene. 2002;21:3592–602.

    Article  CAS  PubMed  Google Scholar 

  5. Britt DE, Yang DF, Yang DQ, et al. Identification of a novel protein, LYRIC, localized to tight junctions of polarized epithelial cells. Exp Cell Res. 2004;300:134–48.

    Article  CAS  PubMed  Google Scholar 

  6. Brown DM, Ruoslahti E. Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell. 2004;5:365–74.

    Article  CAS  PubMed  Google Scholar 

  7. Tian S, Roepman P, Van’t Veer LJ, et al. Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. Biomark Insights. 2010;5:129–38.

    PubMed  PubMed Central  Google Scholar 

  8. Emdad L, Sarkar D, Su ZZ, et al. Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol Ther. 2007;114:155–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Luo Y, Zhang X, Tan Z, et al. Astrocyte elevated gene-1 as a novel clinicopathological and prognostic biomarker for gastrointestinal cancers: a meta-analysis with 2999 patients. PLoS ONE. 2015;10:e0145659.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Emdad L, Das SK, Dasgupta S, et al. AEG-1/MTDH/LYRIC: signaling pathways, downstream genes, interacting proteins, and regulation of tumor angiogenesis. Adv Cancer Res. 2013;120:75–111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Taketa T, Sudo K, Correa AM, et al. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014;12:1139–44.

    Article  PubMed  Google Scholar 

  12. Dong L, Qin S, Li Y, et al. High expression of astrocyte elevated gene-1 is associated with clinical staging, metastasis, and unfavorable prognosis in gastric carcinoma. Tumour Biol. 2015;36:2169–78.

    Article  CAS  PubMed  Google Scholar 

  13. Yang C, Zheng S, Liu Q, et al. Metadherin is required for the proliferation, migration, and invasion of esophageal squamous cell carcinoma and its meta-analysis. Transl Res. 2015;166(614–626):e612.

    Google Scholar 

  14. Li S, Guo X, Ma X, et al. Expression of astrocyte elevated gene-1 closely correlates with the angiogenesis of gastric cancer. Oncol Lett. 2014;7:1447–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.

    Article  Google Scholar 

  16. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187–220.

    Google Scholar 

  17. Yu C, Chen K, Zheng H, et al. Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis. Carcinogenesis. 2009;30:894–901.

    Article  CAS  PubMed  Google Scholar 

  18. Yoo BK, Emdad L, Su ZZ, et al. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest. 2009;119:465–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Zhu K, Dai Z, Pan Q, et al. Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 2011;17:7294–302.

    Article  CAS  PubMed  Google Scholar 

  20. Jian-bo X, Hui W, Yu-long H, et al. Astrocyte-elevated gene-1 overexpression is associated with poor prognosis in gastric cancer. Med Oncol. 2011;28:455–62.

    Article  PubMed  Google Scholar 

  21. Li G, Wang Z, Ye J, et al. Uncontrolled inflammation induced by AEG-1 promotes gastric cancer and poor prognosis. Cancer Res. 2014;74:5541–52.

    Article  CAS  PubMed  Google Scholar 

  22. Baygi ME, Nikpour P. Deregulation of MTDH gene expression in gastric cancer. Asian Pac J Cancer Prev. 2012;13:2833–6.

    Article  PubMed  Google Scholar 

  23. Bhatnagar A, Wang Y, Mease RC, et al. AEG-1 promoter-mediated imaging of prostate cancer. Cancer Res. 2014;74:5772–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Our paper was supported in part by the Grants from NCI, Department of Defense and MDACC (CA129906, CA129926, CA138671, CA1727741, CA150334.01 and CA160445) and Cancer Center Support Grant (NCI Grant P30 CA016672).

Author information

Authors and Affiliations

  1. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd (FC10.3022), Houston, TX, 77030, USA

    Dilsa Mizrak Kaya, Xiaochuan Dong, Yan Xu, Kazuto Harada, Anthony Lopez, Fatemeh G. Amlashi, Irene Thomas, Shumei Song & Jaffer A. Ajani

  2. Department of Biostatistics, The University of Texas MD Anderson Cancer, Houston, TX, USA

    Graciela M. Nogueras-González

  3. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Jeannelyn S. Estrella & Dipen M. Maru

  4. Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Wayne L. Hofstetter

  5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Quynh-Nhu Nguyen

  6. Department of Gastroenterology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Jeffrey H. Lee, Brian Weston & Manoop S. Bhutani

  7. Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Jeremy J. Erasmus

  8. Department of Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Jane E. Rogers

Authors
  1. Dilsa Mizrak Kaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaochuan Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Graciela M. Nogueras-González
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jeannelyn S. Estrella
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuto Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anthony Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fatemeh G. Amlashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wayne L. Hofstetter
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Dipen M. Maru
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Quynh-Nhu Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jeffrey H. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Brian Weston
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Manoop S. Bhutani
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Jeremy J. Erasmus
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Irene Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Jane E. Rogers
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Shumei Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Jaffer A. Ajani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jaffer A. Ajani.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest for this study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mizrak Kaya, D., Dong, X., Nogueras-González, G.M. et al. Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. Med Oncol 34, 135 (2017). https://doi.org/10.1007/s12032-017-0994-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-017-0994-2

Keywords

Search

Navigation